Enzymotec Ltd. announced that Dr. Ariel Katz, the Company's President and Chief Executive Officer, will depart the Company by the end of May 2017, and the Board of Directors has initiated a search for a permanent replacement. Company would like to thank Ariel for his commitment to the Company for the past 17 years; his leadership was instrumental to the transformation of the Company from a small incubator-based company to a public company. Ariel has been a visionary in lipids technology and his work has not only been crucial to the growth of Enzymotec, it has also improved the lives of babies and children around the world.

 With the strong foundation that Ariel has helped build, look forward to executing on the Company's growth opportunities. Dr. Mani Wasserman, the Chair of the Nominations and Corporate Governance Committee of Enzymotec's Board will lead the search for Dr. Katz's replacement.